Research ArticleMetabolism

Epigenetic markers associated with metformin response and intolerance in drug-naïve patients with type 2 diabetes

See allHide authors and affiliations

Science Translational Medicine  16 Sep 2020:
Vol. 12, Issue 561, eaaz1803
DOI: 10.1126/scitranslmed.aaz1803

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

How to mete out metformin

Metformin is the most commonly used drug to treat type 2 diabetes (T2D), though not all patients respond to it, and still, others do not tolerate it. García-Calzón et al. analyzed genome-wide DNA methylation in the blood of drug-naïve patients who were recently diagnosed with T2D. They found that DNA methylation at specific loci associated with future metformin response or tolerance, respectively, across multiple cohorts. These epigenetic markers may have theranostic potential regarding which patients should receive metformin.

View Full Text

Stay Connected to Science Translational Medicine